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Abstract
Cell death due to ischemia is observed  frequently 
under conditions in which an organ is deprived of blood 
flow and is subsequently reperfused, or restored with 
blood supply.  Myocardial ischemia occurs when there is 
an interruption in the blood supply to the heart muscle, 
most often the result of a thrombus (arterial blood clot). 
Subsequent reperfusion of ischemic tissue results in 
extension of the tissue injury beyond that due to the 
deprivation of blood flow; it is due to the reintroduction 
of oxygen to the previously ischemic heart muscle, a 
paradoxical event referred to as “reperfusion injury.” 
Estrogen, a steroid sex hormone, has been shown to protect 
against such cell death.  It is still unknown which of two 
estrogen receptors (ERα/β) mediates the mechanism for 
the protective effects against reperfusion injury.
An in vivo rabbit model was used in which ER-
specific compounds were administered, and the extent of 
myocardial protection was examined.  The ERα agonist 
PPT along with 17β-estradiol produced significant 
reductions in myocardial infarct size when compared to 
vehicle-treated controls, whereas the ERβ agonist DPN 
did not.  The results of the experiment support ERα as a 
mediator of estrogen’s cardioprotection against myocardial 
ischemia and reperfusion injury.
Introduction
 One of the most common types of cellular damage 
in clinical medicine is a result of ischemia.  Ischemia is a 
deficiency of blood supply to a tissue or organ.  Clinical 
examples include arteriosclerosis, thrombotic arterial 
occlusions, and reduced cardiac output.  As the center 
for blood circulation and distribution, it is evident that 
the heart plays a major role in proper blood supply to 
tissues and organs.  The heart muscle (myocardium) is 
itself susceptible to an ischemic incident, usually due to 
an obstruction of one or more of the coronary arteries, 
the vessels which provide nutrient blood flow to the heart 
muscle.  Myocardial ischemia leading to the progressive 
death of heart muscle cells represents the most common 
cause of heart failure.  The sudden obstruction of a major 
coronary artery, most often due to the rapid formation 
of a thrombus is the immediate cause of a myocardial 
infarction (heart attack) and sudden cardiac death.
 When myocardial tissue is subjected to a brief 
ischemic insult (less than 30 minutes), it is possible 
for the cells to recover fully.  However, if ischemia is 
prolonged (45 minutes or more), there exists a subsequent 
transformation of cells from reversible damage to a state 
of irreversibility [1].  With restoration of blood flow, 
termed reperfusion, a paradox is manifested, in which 
oxygen-rich blood,  essential to tissue survival, causes an 
increase in the extent of irreversible cell damage [1].  This 
escalation of cellular damage is referred to as reperfusion 
injury.  Although it frequently occurs in the myocardium, 
reperfusion injury can also affect any other ischemic tissue 
or organ that is subject to restoration of blood flow [1]. 
Such cases include organ transplantation and some types 
of surgery (e.g., open-heart surgery) in which blood flow 
must be interrupted in order to provide a bloodless field 
to permit the surgical procedure to be conducted under 
direct visualization.
 Damage to cells after myocardial ischemia/
reperfusion injury arises through several mechanisms. 
The cells of ischemic tissue recruit neutrophils (the most 
abundant of leukocytes, acting as phagocytes against 
foreign particles) to the site of damage and in turn, become 
activated.  Upon neutrophil activation and accumulation, 
release of reactive oxygen free radicals as well as 
cytotoxic constituents (hydrogen peroxide, hypochlorous 
acid, proteolytic enzymes) released from the invading 
neutrophils cause further damage [1,2].  Previous studies 
have shown that inhibitors of neutrophil activation and 
accumulation attenuate damage to ischemic tissue after 
reperfusion.  Aside from neutrophil activation, tissue 
damage can result from activation of the complement 
system, which is composed of two pathways, converging to 
form the membrane attack complex (MAC), which forms 
a pore in the cell membrane.  When activated, the products 
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Materials and Methods
Surgical Preparation
 Female New Zealand White rabbits were 
anesthetized with ketamine and xylazine, administered 
intramuscularly.  Sodium pentobarbital was administered 
intravenously as needed throughout the duration of the 
experiment to maintain a state of surgical anesthesia.  An 
endotracheal tube was inserted that allowed for controlled 
respiration with the use of a positive pressure respirator. 
The left jugular vein was isolated and a catheter was 
inserted for drug administration and blood sampling.  A 
Millar™ micro pressure transducer was inserted into the 
left carotid artery to record the aortic blood pressure, 
and an electrocardiogram was monitored throughout the 
duration of the protocol.  The chest was opened through 
the left side to expose the heart, and the pericardium was 
opened to expose the surface of the heart and in order to 
visualize the coronary arteries, thereby concluding the 
preliminary surgical preparation[Figure 1].
Administration
The animals were allowed to equilibrate for 15 
minutes after the surgery.  After the stabilization period, 
one of four drug treatments was administered:  vehicle 
(n = 8), composed of 20% dimethyl sulfoxide (DMSO) 
and 80% polyethylene glycol (PEG); 17β-estradiol (10 
µg; n = 8), non-selective, binding to both ERα and ERβ; 
4,4’,4’’-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)triphenol, 
or PPT (3 mg/kg; n = 8), a selective ERα agonist; or 2,3-
bis(4-Hydroxyphenyl)-propionitrile, or DPN (3 mg/kg; 
n = 8), a selective ERβ agonist.  After 30 minutes, the 
left anterior descending coronary artery was occluded by 
passing a suture underneath the artery and tying it around 
a segment of plastic tubing thereby occluding the vessel 
[Figure 2].  Regional myocardial ischemia was maintained 
for a period of 30 minutes and was confirmed by a distinct 
of the complement cascade can damage cells indirectly 
through recruitment of neutrophils (anaphylatoxins C5a 
and C3a), or through cell lysis elicited by assembly of 
the MAC (C5b-9) on the cell membranes in the area of 
reperfusion [2].
 The incidence of coronary vascular disease 
increases two-fold among women after menopause, 
which is associated with a decrease in the synthesis and 
release of estrogen.  However, it has been demonstrated 
that the administration of estrogen may have adverse 
effects due to the lack of specificity for heart muscle. 
Thus, hormone replacement therapy, once believed to be 
beneficial for the prevention of cardiovascular events in 
the post-menopausal patient, has limitations to its usage 
[3].  Several controlled, double-blind clinical trials have 
generated unfavorable outcomes, and the recommendation 
is for short-term usage of hormone replacement therapy 
for the relief of vasomotor symptoms (e.g., hot flashes). 
However, recent experimental studies have shown 
estrogen (17β-estradiol) to be cardioprotective in terms of 
reducing the extent of reperfusion injury.  Two estrogen 
receptors (ER) have been identified, mainly ERα and ERβ. 
The exact mechanism by which estrogen protects against 
reperfusion injury is still unknown [3].  The focus of the 
study was to learn more about the mechanism behind this 
cardioprotection, and specifically, whether it is mediated 
through ERα or ERβ.  Experimental data show 17β-
estradiol, the naturally occurring form of the hormone 
estrogen, to be protective, but finding a more selective 
compound would provide the benefits without the adverse 
effects exerted upon the uterus, breast and blood clotting 
system.  To do this, estrogen receptor-specific compounds 
were used and examined for the extent to which they 
offered cardioprotection against myocardial ischemia and 
reperfusion injury.
Figure 1:  Experimental Protocol:  A schematic representation of the entire experimental protocol.  The study 
began with a surgical preparation, then allowing the heart to equilibrate for 15 minutes.  After equilibration, 
one of the four compounds was administered intravenously, and allowed to circulate for 30 minutes.  After 
this, ischemia was induced by ligating the coronary artery, and lasted for 30 minutes.  Following ischemia, 
the ligature was removed and the heart was reperfused for 4 hours.
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not subjected to ischemia.  The heart was then removed 
from the apparatus and three cross sections of the left 
ventricular tissue were obtained and examined [Figure 3]. 
Heart sections were traced and scanned.  Adobe Photoshop 
was used to calculate the number of pixels for the areas of 
total left ventricle, area at risk, and infarct size.  Along with 
examining the myocardial tissue, blood samples were also 
analyzed.  Samples were taken at different time points in 
the experiment for all treatment groups and were assessed 
for troponin I levels.  Troponin is a protein complex, an 
isoform that exists in the cardiac muscle (cTnI), and its 
levels correlate positively with tissue damage.  Antibodies 
Figure 2:  The Heart:  A picture of an animated heart.  
The left anterior descending (LAD) coronary artery is 
identified.  The location of the ligature is also marked, 
and some tissue below the occlusion was subject to 
ischemia.  Finally, three cross-sectional slices of left 
ventricular tissue were examined for infarct size.
purple color demarcating the ischemic myocardium and 
accompanied by elevation of the ST-segment in the Lead 
II electrocardiogram.  The final surgical step was the 
restoration of blood flow to the previously ischemic region 
by removal of the occlusive ligature and reperfusal of the 
heart for 4 hours at which point the surgical portion of the 
experimental protocol was completed.
Analysis
The degree of protection afforded by each 
treatment was assessed by determining the extent 
of myocardial tissue undergoing irreversible tissue 
injury (myocardial infarction).  After the 4 hours of 
reperfusion, the hearts were removed and placed on a 
Langendorff perfusion apparatus that circulated buffer 
through the heart, clearing the coronary vascular bed of 
blood cellular elements and plasma.  A solution of 1% 
triphenyltetrazolium chloride (TTC) in phosphate buffer 
was passed through the heart, staining the viable, non-
infarct tissue that was subject to ischemia a bright red 
color.  The cells with irreversible damage do not stain, 
and  remain a pale yellow color.  The coronary artery was 
then ligated just above the original point of occlusion that 
induced myocardial ischemia to insure the same region 
of myocardium was now tied off (area at risk).  After 
stopping the perfusion pump, a solution of Evans blue dye 
was infused through the heart, marking all tissue that was 
Figure 3:  Cross-Sectional Tissue:  Once the experimental 
protocol was completed, the heart was hung on a 
Langendorff apparatus.  A solution of TTC was passed 
through the heart, staining all viable cells a red color, while 
leaving the infarct cells a pale yellow color.  The red and 
yellow regions together make up the area at risk, the region 
subject to ischemia.  After this, the coronary artery was 
occluded at the same location of the initial ligation (the one 
inducing ischemia during the protocol) and an Evans blue 
dye was passed through the heart staining the remainder of 
the myocardium a blue color.  This demarcated the normal 
zone, or the tissue never subjected to ischemia throughout 
the entire experiment.
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specific to cardiac troponin I were used to detect levels of 
the complex at different stages during the experiment.  
Results
Administration
The area at risk as a percent of the total left 
ventricle was calculated to ensure consistency with the 
amount of tissue subject to ischemia from animal to 
animal.  In determining the area at risk (AR) as a percent 
of the total left ventricular tissue (LV), the treatment group 
averages were as follows:  59.2 ± 3.0 with vehicle, 55.2 
± 2.8 with 17β-estradiol, 59.4 ± 4.2 with PPT, and 58.7 ± 
2.2 with DPN [Figure 4].
 
Analysis
The infarct size as a percent of the area at risk 
(tissue subject to ischemia) was calculated to determine 
the extent of damage in each treatment group.  When 
calculating the infarct zone (IZ) as a percent of the area 
at risk (AR), there were significant differences among 
the treatment groups.  The average infarct size decreased 
among the 17β-estradiol (ERα/β agonist) group (17.7 ± 
2.9) when compared to the vehicle group (45.3 ± 2.4; 
p < 0.001).  The group pretreated with PPT (ERα) also 
showed a similar decrease in infarct size (18.1 ± 2.3) when 
compared to vehicle (p < 0.001).  The ERβ agonist DPN, 
however, showed no significant reduction of infarct size 
(44.5 ± 4.1) as compared with vehicle [Figure 5].
Troponin levels seemed to increase from the 
baseline to the 2-hour reperfusion mark, and even more at 
the 4-hour reperfusion mark.  However, the rabbits treated 
with 17β-estradiol and PPT showed a lesser increase in 
troponin levels than in vehicle or DPN treated animals 
[Figure 6].
Discussion
When analyzing the results, the data showed that 
a consistent amount of tissue was subject to ischemia 
during the surgical procedure across all treatment groups. 
Therefore, any differences in infarct size were due to the 
drug treatment interventions.  The calculations indicate 
that both 17β-estradiol and PPT result in a smaller region 
Figure 4:  Area at Risk:  This graph depicts the amount of tissue that was considered at risk (AR) as a percent of the 
total left ventricle tissue (LV) among all four treatment groups.  The four groups had similar percentages of area at 
risk, demonstrating the consistency in the amount of tissue subject to ischemia throughout the experiments.
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of infarct tissue, suppressing the damage caused by 
reperfusion injury.  The DPN group did not show this 
decrease in tissue damage, exhibiting similar results to 
the control group.  The reduced troponin levels in the 
17β-estradiol- and PPT-treated groups further support 
the evidence for cardioprotection elicited by these drugs. 
The data compiled from this study, consequently, do 
not support ERβ as having a major role in mediating 
estrogen’s protective activity.  However, results from this 
experiment do indeed show evidence for ERα as a primary 
component in estrogen’s mechanism for cardioprotection 
against myocardial ischemia and reperfusion injury.  With 
these results and future studies, more will be known of 
the mechanism behind estrogen’s cardioprotection.  The 
adverse effects of current hormone replacement therapy 
will be minimized without compromising the benefits 
through novel therapeutic interventions.
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